Views & Analysis | Perspectives on pharma industry issues

Oncology

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Digital

Google AI Overviews: What it means for pharma

EVERSANA INTOUCH’s 2026 Pharma AI Overviews Report covers the rapid evolution within the Google AI Overviews landscape.

R&D

Clinical Trials Round-Up: March and April 2026

March and April offered no shortage of talking points for the clinical trials community.

Sales & Marketing

Sponsored

12 Questions with Shauna Lord

Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.

Digital

HCP holds agenticc AI in open palmed hand against dark background

Veeva Agentic Commercial: Evidence‑led AI for pharma

Veeva's Commercial Cloud aims to deliver the right medicines to more patients.

Views & Analysis

Secret US-UK talks on drug pricing revealed

Despite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at the time of writing – the need to strike new trade deals has led to secret trade discussions be

Views & Analysis

Harnessing the potential of AI in commercial life sciences

Artificial intelligence (AI) has gained significant momentum in life sciences over the past few years.

Views & Analysis

How augmented reality is leading to real world patient impro...

It’s been a long time since the summer of 2016 when Pokémon Go was the biggest news in augmented reality (AR).

Sales & Marketing

Sponsored

12 Questions with Shauna Lord

Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.

Sales & Marketing

Sponsored

Solution Spotlight: IQVIA CTFS Site Payments

IQVIA Clinical Trial Financial Suite (CTFS) is a next-generation platform designed to modernise clinical trial financial operations.

Digital

Google AI Overviews: What it means for pharma

EVERSANA INTOUCH’s 2026 Pharma AI Overviews Report covers the rapid evolution within the Google AI Overviews landscape.

Digital

Veeva Agentic Commercial: Evidence‑led AI for pharma

Veeva's Commercial Cloud aims to deliver the right medicines to more patients.

Market Access

Industry exercises option for midpoint review of VPAG Invest...

Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?

Market Access

Approval designed from day one: Building global-ready regula...

The global pharmaceutical landscape is increasingly defined by the necessity for clinical acceleration without compromising data integrity.

Oncology

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ASCO 2026: Powerful evidence for the microbiome in oncology,...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother